04:38 PM EDT, 03/11/2024 (MT Newswires) -- Ocular Therapeutix ( OCUL ) reported late Monday a Q4 loss of $0.35 per diluted share, wider than a loss of $0.24 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.30.

Net revenue for the quarter ended Dec. 31 was $14.8 million, up from $14.1 million a year earlier. Analysts surveyed by Capital IQ expected $15.7 million.

The company's shares fell more than 5% in after-hours activity.

Price: 9.22, Change: -0.51, Percent Change: -5.24